Q-omics provides the consensus-scored UBE2O profile across patient tissues and cancer cell-line models. UBE2O expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, UBE2O is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, UBE2O protein abundance shows 24,328 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where UBE2O shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2O — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2O survival associations across molecular data types. UBE2O RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2O RNA expression–survival associations across cancer types. High UBE2O expression shows unfavorable associations in KIRP, LIHC, MESO, KICH, ACC and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for UBE2O RNA expression.
This table summarizes UBE2O tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UBE2O. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2O shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, KIRP, KIRC and BLCA. The HNSC box plot shows higher UBE2O RNA expression in tumor versus normal tissue (log2 FC = +0.900, t-test p < 0.001).
This table shows molecular features associated with UBE2O in patient tissues and cancer cell lines. In patient samples, UBE2O shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2O RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
